NFE2L2 and nonpapillary renal cell carcinoma: Overlapping with clear cell renal cell carcinoma (ccRCC), the nuclear factor erythroid 2-related factor 2 (NRF2)-dependent inhibition of ferroptosis also induces sorafenib resistance [32].